Clinical trial · Interventional
The Application Value of Spectral CT in the Accurate Staging of Gastric Cancer
NCT06977386CI-TRIAL-00089872not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Spectral CT was used to prospectively collect medical images and clinical data related to gastric cancer, evaluate the effect of image quality in the diagnosis of gastric cancer, and evaluate the application value in the accurate staging of gastric cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| To explore the value of spectral CT in the diagnosis and treatment of gastric cancer | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- The application value of spectral CT in the accurate staging of gastric cancer
- description
- Prospectively collect medical images and clinical data related to gastric cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of gastric cancer.Patients diagnosed with gastric cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of gastric cancer patients was assessed by two radiologists, and finally statistical analysis was performed.
- interventionNames
- Diagnostic Test: To explore the value of spectral CT in the diagnosis and treatment of gastric cancer
Primary outcomes (1)
- measure
- Pathological TNM staging
- timeFrame
- 1 day
- description
- Pathological examination information: The pathology results using surgery/biopsy data are the gold standard, and the depth of tumor invasion, lymph node metastasis, and distant metastasis are recorded
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * (a)Patients with pathologically confirmed gastric cancer; * (b) aged ≥ 18 years old; * (c) have not received chemoradiotherapy or surgery. Exclusion Criteria: * (a)Combined with other primary tumors; * (b) The image quality does not meet the diagnostic criteria; * (c)Those who cannot tolerate CT examination.
References
Publications (0)
Data not yet available
No reference posted for this study.